{
    "eid": "2-s2.0-85064121799",
    "title": "Impact of POR and CYP3A5 polymorphisms on trough concentration to dose ratio of tacrolimus in the early post-operative period following kidney transplantation",
    "cover-date": "2018-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "CYP3A5",
        "Genetic polymorphisms",
        "Kidney transplantation",
        "POR",
        "Tacrolimus"
    ],
    "authors": [
        "Annop Phupradit",
        "Somratai Vadcharavivad",
        "Atiporn Ingsathit",
        "Surasak Kantachuvesiri",
        "Nutthada Areepium",
        "Supasil Sra-ium",
        "Titinun Auamnoy",
        "Chonlaphat Sukasem",
        "Vasant Sumethkul",
        "Chagriya Kitiyakara"
    ],
    "citedby-count": 13,
    "ref-count": 48,
    "ref-list": [
        "KDIGO clinical practice guideline for the care of kidney transplant recipients",
        "Therapeutic monitoring of calcineurin inhibitors for the nephrologist",
        "Clinical pharmacokinetics of tacrolimus",
        "Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation",
        "The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation",
        "A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients",
        "Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients",
        "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I",
        "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing",
        "Optimization of initial tacrolimus dose using pharmacogenetic testing",
        "A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation",
        "The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients",
        "Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients",
        "The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients",
        "The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients",
        "Impact of PPARA and POR polymorphisms on tacrolimus pharmacokinetics and new-onset diabetes in kidney transplant recipients",
        "Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus",
        "A lack of significant effect of POR*28 allelic variant on tacrolimus exposure in kidney transplant recipients",
        "Association of CYP3A5 and POR polymorphisms with the maintenance tacrolimus dosage requirement in Thai recipients of kidney transplants",
        "Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients",
        "Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection",
        "Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions",
        "Haplotype blocks and linkage disequilibrium in the human genome",
        "Linkage disequilibrium of evolutionarily conserved regions in the human genome",
        "Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group",
        "Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients",
        "G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences",
        "Cubic exact solutions for the estimation of pairwise haplotype frequencies: Implications for linkage disequilibrium analyses and a web tool \u201cCubeX",
        "Genetic variability in CYP3A5 and its possible consequences",
        "Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation",
        "Pharmacogenomics of human P450 oxidoreductase",
        "NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer",
        "Three-dimensional structure of NADPH-cytochrome P450 reductase: Prototype for FMN- And FAD-containing enzymes",
        "Consequences of POR mutations and polymorphisms",
        "Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase",
        "Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: Toward updated genotype-based dosage guidelines",
        "Worldwide distribution of cytochrome P450 alleles: A meta-analysis of population-scale sequencing projects",
        "Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs",
        "Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: Comparison with similar data from other populations",
        "Pharmacokinetic considerations relating to tacrolimus dosing in the elderly",
        "The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation",
        "Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation",
        "Population pharmacokinetics of tacrolimus in kidney transplant patients",
        "Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling",
        "Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit",
        "Total plasma protein effect on tacrolimus elimination in kidney transplant patients\u2013population pharmacokinetic approach"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chon Buri",
            "@id": "122402756",
            "affilname": "Bur-apha University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122402756",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University",
        "Astellas Pharma"
    ]
}